List of Trelegy Ellipta drug patents

Trelegy Ellipta is owned by Glaxosmithkline.

Trelegy Ellipta contains Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate.

Trelegy Ellipta has a total of 15 drug patents out of which 1 drug patent has expired.

Expired drug patents of Trelegy Ellipta are:

  • US7776895

Trelegy Ellipta was authorised for market use on 18 September, 2017.

Trelegy Ellipta is available in powder;inhalation dosage forms.

Trelegy Ellipta can be used as method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application, method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd, indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; and asthma, indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema, method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application, maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol.

The generics of Trelegy Ellipta are possible to be released after 29 November, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(a month from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(4 months ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(4 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Sep 9, 2023
New Indication (I) Sep 9, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol; Indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; And asthma; Maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in